Nektar Therapeutics got a consolation prize of $135 million from Pfizer--and a fresh shot at signing a new partner--to calm any upset feelings about Pfizer's abandonment of Exubera [1], a once mighty prospect in the world of inhalable diabetes therapies. In return, both parties are absolved of any further obligations for Exubera or the next-generation version of the therapy that Nektar has in Phase I. And if Nektar lines up a new partner, Pfizer has agreed to hand over any rights it has in the two products.
- check out Pfizer's release [2]
- here's the report [3] on Nektar from RTT News
Related Articles:
Pfizer kills off Exubera, hunts for deals. Report [1]
Exubera becoming a big disappointment for Pfizer. Report [4]
UK: Exubera not worth the price. Report [5]
FDA approves Pfizer's inhaled insulin. Report [6]
Links:
[1] http://www.fiercepharma.com/story/pfizer-kills-exubera-hunts-deals/2007-10-18
[2] http://www.fiercebiotech.com/press-releases/press-release-pfizer-and-nektar-reach-agreement-exubera
[3] http://www.rttnews.com/sp/Quickfactsnew.asp?item=92
[4] http://www.fiercebiotech.com/story/exubera-becoming-a-big-disappointment-for-pfizer/2007-04-10
[5] http://www.fiercebiotech.com/story/spotlight-uk-exubera-not-worth-the-price/2006-04-18
[6] http://www.fiercebiotech.com/story/fda-approves-pfizer-s-inhaled-insulin/2006-01-30